Table 2

Changes in Clinical Parameters After 16-Week Treatments With Pioglitazone and Glimepiride

PioglitazoneGlimepiridep Value Between Groups
Weight, kg
 Baseline64.4 ± 12.565.3 ± 10.80.794
 Post-treatment65.1 ± 13.065.8 ± 10.40.858
 p value vs. baseline0.0800.153
Waist circumference, cm
 Baseline88.3 ± 9.889.0 ± 10.50.806
 Post-treatment89.5 ± 9.589.4 ± 10.00.979
 p value vs. baseline0.0580.484
Systolic blood pressure, mm Hg
 Baseline128.0 ± 12.3123.5 ± 13.30.239
 Post-treatment124.1 ± 14.9123.7 ± 14.10.936
 p value vs. baseline0.1490.907
Diastolic blood pressure, mm Hg
 Baseline70.8 ± 9.069.0 ± 9.30.511
 Post-treatment70.4 ± 9.868.1 ± 9.80.452
 p value vs. baseline0.8190.458
LDL cholesterol, mg/dl
 Baseline108.4 ± 23.8117.6 ± 24.80.210
 Post-treatment106.4 ± 27.7118.1 ± 19.80.116
 p value vs. baseline0.7140.903
HDL cholesterol, mg/dl
 Baseline49.9 ± 12.851.3 ± 13.00.723
 Post-treatment54.6 ± 14.953.3 ± 12.50.755
 p value vs. baseline0.0170.161
Triglycerides, mg/dl
 Baseline105.0 (79.5–125.5)120.0 (74.8–164.0)0.965
 Post-treatment120.0 (80.5–148.5)119.5 (85.0–207.8)0.611
 p value vs. baseline0.4310.153
Fasting plasma glucose, mg/dl
 Baseline121.0 (105.5–140.0)129.0 (119.5–145.5)0.249
 Post-treatment110.0 (100.5–120.5)120.0 (111.8–133.5)0.004
 p value vs. baseline0.0010.003
Fasting plasma insulin, μU/ml
 Baseline6.80 (4.55–11.20)4.85 (3.63–8.45)0.157
 Post-treatment6.40 (4.20–10.45)5.70 (4.10–7.53)0.681
 p value vs. baseline0.1440.592
Hemoglobin A1c, %
 Baseline6.61 ± 0.736.85 ± 0.640.247
 Post-treatment6.15 ± 0.426.50 ± 0.510.014
 p value vs. baseline<0.001<0.001
High-sensitivity CRP, mg/l
 Baseline0.78 (0.34–1.93)0.61 (0.35–1.47)0.466
 Post-treatment0.53 (0.27–1.15)0.93 (0.45–2.00)0.101
 p value vs. baseline0.2280.018

Values are mean ± SD or median (interquartile range).

Abbreviations as in Table 1.